Publication
Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study.
Jeremy S Abramson, Tanya Siddiqi, Leo I Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Manali Kamdar, David G Maloney, Mazyar Shadman, Charalambos Andreadis, Alison Sehgal, Scott R Solomon, Nilanjan Ghosh, Juliana E Hidalgo-López, Jing Wang, Xue Ding, Ken Ogasawara, Ashvin Singh, M Lia Palomba
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
We present 5-year survival results in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) from TRANSCEND NHL 001 (TRANSCEND), including data from the separate long-term follow-up (LTFU) study. Overall, 345 patients were leukapheresed and 270 received lisocabtagene maraleucel…
Read on PubMedLinked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 2
- trialNCT02631044registry_reference1.00
- trialNCT03435796registry_reference1.00
Candidate 1
- cancerNon-Hodgkin Lymphomadictionary0.60
Registered trialsNCT02631044NCT03435796
Curated evidence
Evidence citing this paper (0)
Data not yet available